---
title: "VK2735 in Chronic weight management: SUNRISE-2"
description: "Formulary evidence on VK2735 in Chronic weight management: SUNRISE-2. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 2 further headings. 29 evidence topics quoted from 14 sources."
canonical: "https://www.evicenter.com/drugs/vk2735--chronic-weight-management/clinical-evidence/sunrise-2"
published: "2026-11-15T21:45:47-05:00"
modified: "2026-11-15T21:45:47-05:00"
---

# VK2735 in Chronic weight management: SUNRISE-2

<a id="heading-3.1.4"></a>

## 3.1.4 SUNRISE-2

<a id="heading-3.1.4.1"></a>

### 3.1.4.1 Objective

<a id="topic-3.1.4.1-1"></a>

#### Registry objective: oral VK2735 in adults with type 2 diabetes

> “This study is one of two planned Phase 3 studies to support the weight management indication for VK2735 Oral in obese (BMI ≥ 30 kg/m2) or overweight (BMI ≥ 27 kg/m2) adults with Type 2 Diabetes Mellitus.”
> “This is a Phase 3, multicenter, 68-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 oral formulation in adults with Type 2 Diabetes Mellitus (T2DM) who are obese or overweight.”

Source: [ClinicalTrials.gov NCT07868939](https://clinicaltrials.gov/study/NCT07868939)

<a id="topic-3.1.4.1-2"></a>

#### Company-stated objective of the SUNRISE program

> “The SUNRISE Phase 3 program includes two studies evaluating oral VK2735: one in adults with obesity and another in obese or overweight adults with type 2 diabetes.”
> “Each study is a randomized, double-blind, placebo-controlled, multicenter trial designed to assess the efficacy and safety of VK2735, with patients receiving once-daily oral VK2735 for 68 weeks.”

Source: [Viking Therapeutics SUNRISE initiation release (2026)](https://ir.vikingtherapeutics.com/2026-10-14-Viking-Therapeutics-Announces-Initiation-of-VK2735-Oral-Phase-3-Clinical-Program-in-Patients-with-Obesity)

<a id="heading-3.1.4.2"></a>

### 3.1.4.2 Location and Study Date

<a id="topic-3.1.4.2-1"></a>

#### Registry status and estimated dates

> “Not yet recruiting”
> “2026-11”
> “2028-10”
> “2028-12”

Source: [ClinicalTrials.gov NCT07868939](https://clinicaltrials.gov/study/NCT07868939)

<a id="topic-3.1.4.2-2"></a>

#### Company-reported initiation and enrollment status

> “today announced the initiation of the SUNRISE Phase 3 clinical program for oral VK2735”

Source: [Viking Therapeutics SUNRISE initiation release (2026)](https://ir.vikingtherapeutics.com/2026-10-14-Viking-Therapeutics-Announces-Initiation-of-VK2735-Oral-Phase-3-Clinical-Program-in-Patients-with-Obesity)

> “SUNRISE Oral Phase 3 VK2735 Program Initiated; SUNRISE 1 & 2 Trials Underway.”

Source: [Viking Therapeutics third quarter 2026 results release (2026)](https://ir.vikingtherapeutics.com/2026-10-28-Viking-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update)

> “Initiated 4Q26”
> “Phase 3 SUNRISE trials underway”

Source: [Viking Therapeutics corporate presentation (2026)](https://ir.vikingtherapeutics.com/download/Viking+Therapeutics+Corporate+Presentation+November+2026.pdf)

> “Pretty early days there, but I think we are satisfied with what we see at this point.”

Source: [Viking Therapeutics third quarter 2026 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/714458-q3-2026/)

<a id="topic-3.1.4.2-3"></a>

#### Study sites shared with the VANQUISH program

> “There certainly is some overlap, especially for the sites that have performed well for us. We certainly want to retain them.”

Source: [Viking Therapeutics third quarter 2026 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/714458-q3-2026/)

<a id="topic-3.1.4.2-4"></a>

#### Expected timing of data

> “Data Expected 2028”

Source: [Viking Therapeutics corporate presentation (2026)](https://ir.vikingtherapeutics.com/download/Viking+Therapeutics+Corporate+Presentation+November+2026.pdf)

> “The oral, I think of that as always about 12- 18 months behind the SubQ.”

Source: [Viking Therapeutics Jefferies conference transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/678533-jefferies-global-healthcare-conference-2026/)

<a id="topic-3.1.4.2-5"></a>

#### Planned start date before initiation

> “Based on feedback from the agency, the company plans to advance oral VK2735 into Phase 3 development for obesity, expected to begin in 3Q26.”

Source: [Viking Therapeutics fourth quarter 2025 results release (2026)](https://ir.vikingtherapeutics.com/2026-02-11-Viking-Therapeutics-Reports-Fourth-Quarter-and-Year-End-2025-Financial-Results-and-Provides-Corporate-Update)

> “We currently expect to initiate this program in the Q4 of this year and will provide more details on study design at that time.”

Source: [Viking Therapeutics first quarter 2026 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/555372-q1-2026/)

<a id="heading-3.1.4.3"></a>

### 3.1.4.3 Study Design

<a id="topic-3.1.4.3-1"></a>

#### Randomized, double-blind, placebo-controlled, parallel-arm design

> “This is a Phase 3, multicenter, 68-week randomized, double-blind, placebo-controlled, parallel arm study”

Source: [ClinicalTrials.gov NCT07868939](https://clinicaltrials.gov/study/NCT07868939)

> “Each study is a randomized, double-blind, placebo-controlled, multicenter trial designed to assess the efficacy and safety of VK2735, with patients receiving once-daily oral VK2735 for 68 weeks.”

Source: [Viking Therapeutics SUNRISE initiation release (2026)](https://ir.vikingtherapeutics.com/2026-10-14-Viking-Therapeutics-Announces-Initiation-of-VK2735-Oral-Phase-3-Clinical-Program-in-Patients-with-Obesity)

<a id="topic-3.1.4.3-2"></a>

#### Treatment period, screening, and follow-up

> “4 wk screening”
> “Double-Blind Treatment, Weeks 1-68”

Source: [Viking Therapeutics corporate presentation (2026)](https://ir.vikingtherapeutics.com/download/Viking+Therapeutics+Corporate+Presentation+November+2026.pdf)

> “You got to be 52 weeks at the post titration dose, but the titration window is shorter, so makes the whole trial shorter.”

Source: [Viking Therapeutics Morgan Stanley conference transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/744429-morgan-stanley-24th-annual-global-healthcare-conference/)

<a id="topic-3.1.4.3-3"></a>

#### Separate trial in type 2 diabetes, modeled on the VANQUISH program

> “The SUNRISE oral Phase 3 program will closely mirror the ongoing VANQUISH Phase 3 program evaluating the subcutaneous formulation”

Source: [Viking Therapeutics third quarter 2026 results release (2026)](https://ir.vikingtherapeutics.com/2026-10-28-Viking-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update)

> “As I said earlier, probably is going to look like the VANQUISH program. So I think you could do a single study and have diabetes patients in there as well, but it's likely cleaner to keep them separate and do two studies.”

Source: [Viking Therapeutics fourth quarter 2025 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/401860-q4-2025/)

> “Design elements, it'll be two studies, smaller and shorter in duration than the VANQUISH studies.”

Source: [Viking Therapeutics second quarter 2026 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/657331-q2-2026/)

<a id="topic-3.1.4.3-4"></a>

#### FDA draft guidance: trials enrolling only participants with diabetes

> “Because the observed treatment effect of a drug might be substantially different in”
> “subjects taking concomitant glucose-lowering medications, it may be reasonable to”
> “conduct one or more trials that enroll only subjects with diabetes at baseline”

Source: [FDA weight reduction draft guidance (2025)](https://www.fda.gov/media/71252/download)

<a id="topic-3.1.4.3-5"></a>

#### FDA end-of-phase 2 meeting for the oral tablet

> “In December 2025, Viking held an end-of-Phase 2 meeting with the FDA to discuss potential next steps for oral VK2735.”

Source: [Viking Therapeutics fourth quarter 2025 results release (2026)](https://ir.vikingtherapeutics.com/2026-02-11-Viking-Therapeutics-Reports-Fourth-Quarter-and-Year-End-2025-Financial-Results-and-Provides-Corporate-Update)

> “As far as the sizes of the studies, I mean, we, of course, outlined our anticipated clinical development plan to the FDA, and we feel comfortable with the responses that we're okay to proceed at the design level that we presented.”
> “As far as the oral end-of-Phase II and the subQ end-of-Phase II, we're not going to get into the details of the discussions, but I'd say the feedback was consistent with what we heard from the end-of-Phase II for the subQ formulation.”

Source: [Viking Therapeutics fourth quarter 2025 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/401860-q4-2025/)

> “The FDA, we had an end-of-phase II meeting in the fourth quarter last year, and the FDA they pointed out risks going from phase II to phase III, but they were okay with it.”

Source: [Viking Therapeutics Jefferies conference transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/678533-jefferies-global-healthcare-conference-2026/)

> “both the subq and the oral, we asked in an end of phase II meeting, can we leverage the human data, safety data that will be generated in the subq phase III program for the oral phase III program? The FDA indicated, everything works out, yes.”

Source: [Viking Therapeutics Morgan Stanley conference transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/744429-morgan-stanley-24th-annual-global-healthcare-conference/)

<a id="topic-3.1.4.3-6"></a>

#### Planned extension period

> “With the oral extension, we do plan to incorporate extensions to the SUNRISE studies, but it is premature really to talk about what those doses might look like.”

Source: [Viking Therapeutics third quarter 2026 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/714458-q3-2026/)

<a id="heading-3.1.4.4"></a>

### 3.1.4.4 Eligibility Criteria

<a id="topic-3.1.4.4-1"></a>

#### Inclusion criteria: body mass index and type 2 diabetes

> “Age ≥18 years of age at the time of signing the informed consent.”
> “Body mass index (BMI) ≥ 27 kg/m2”
> “Have Type 2 Diabetes Mellitus according to the American Diabetes Association (See Section 12.5), with HbA1c ≥ 7% to ≤ 11% at screening, on stable therapy for the last 3 months prior to Screening.”
> “Type 2 Diabetes Mellitus may be treated with diet/exercise alone or any oral glycemic-lowering agent (as per local labeling), EXCEPT for amylin analogues or dipeptidyl peptidase 4 (DPP-4) inhibitors or GLP-1R agonists or dual GLP-1/ glucose-dependent insulinotropic polypeptide (GIP) receptor agonists.”

Source: [ClinicalTrials.gov NCT07868939](https://clinicaltrials.gov/study/NCT07868939)

<a id="topic-3.1.4.4-2"></a>

#### Exclusion criteria: diabetes-related

> “Have Type 1 Diabetes Mellitus, history of ketoacidosis or hyperosmolar state/coma or any other types of diabetes except Type 2 Diabetes Mellitus (T2DM)”
> “Have had 1 or more episodes of severe hypoglycemia and/or 1 or more episode of hypoglycemia unawareness within 6 months of screening”
> “Have non-proliferative diabetic retinopathy that requires acute treatment OR diabetic macular edema OR proliferative diabetic retinopathy identified during a dilated fundoscopy examination performed within 3 months of screening.”

Source: [ClinicalTrials.gov NCT07868939](https://clinicaltrials.gov/study/NCT07868939)

<a id="topic-3.1.4.4-3"></a>

#### Exclusion criteria: other

> “Self-reported body weight change of 5% or more within 3 months of screening”
> “Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2)”
> “History of acute or chronic pancreatitis”

Source: [ClinicalTrials.gov NCT07868939](https://clinicaltrials.gov/study/NCT07868939)

<a id="topic-3.1.4.4-4"></a>

#### Company description of the enrolled population

> “SUNRISE-2 will enroll adults with type 2 diabetes who are obese or overweight.”

Source: [Viking Therapeutics SUNRISE initiation release (2026)](https://ir.vikingtherapeutics.com/2026-10-14-Viking-Therapeutics-Announces-Initiation-of-VK2735-Oral-Phase-3-Clinical-Program-in-Patients-with-Obesity)

> “Targeting enrollment of 560 adults with type 2 diabetes who have obesity or are overweight”

Source: [Viking Therapeutics corporate presentation (2026)](https://ir.vikingtherapeutics.com/download/Viking+Therapeutics+Corporate+Presentation+November+2026.pdf)

<a id="heading-3.1.4.5"></a>

### 3.1.4.5 Treatment

<a id="topic-3.1.4.5-1"></a>

#### Registry arms: doses described as dose levels

> “VK2735 Dose level 1 orally once daily”
> “VK2735 Dose level 2 orally once daily”
> “VK2735 Dose level 3 orally once daily”
> “Placebo comparator orally once daily”
> “VK2735 Oral is a peptide GLP-1 and GIP dual agonist administered once daily”

Source: [ClinicalTrials.gov NCT07868939](https://clinicaltrials.gov/study/NCT07868939)

<a id="topic-3.1.4.5-2"></a>

#### Company-stated doses: 27.5 mg, 35 mg, and 55 mg once daily

> “Participants in both trials will be randomly assigned to one of four treatment groups receiving once-daily VK2735 doses of 27.5 mg, 35 mg, 55 mg, or placebo.”

Source: [Viking Therapeutics SUNRISE initiation release (2026)](https://ir.vikingtherapeutics.com/2026-10-14-Viking-Therapeutics-Announces-Initiation-of-VK2735-Oral-Phase-3-Clinical-Program-in-Patients-with-Obesity)

> “Participants in each trial will be randomized to one of four treatment groups receiving once-daily VK2735 doses of 27.5 mg, 35 mg, 55 mg, or placebo.”

Source: [Viking Therapeutics third quarter 2026 results release (2026)](https://ir.vikingtherapeutics.com/2026-10-28-Viking-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update)

<a id="topic-3.1.4.5-3"></a>

#### Dose titration schedule

> “There are four-week titration blocks. The 27.5 starts at 10 for four weeks, 17.5 for four weeks, and then that spends 60 weeks at 27.5. Then we look at the highest dose, the 55 mg. That goes up in four-week blocks as well, and you end up at 55 mg for 52 weeks.”
> “The tablet strengths are 27.5 and 17.5, and so that is what leads to the multiples of those numbers as the final dosing numbers.”

Source: [Viking Therapeutics third quarter 2026 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/714458-q3-2026/)

<a id="topic-3.1.4.5-4"></a>

#### Rationale for the selected doses: tablet burden and cost of goods

> “In going to the SUNRISE dose selection, a lot went into the dose selection there. We heard from the phase II experience, we want to lower the tablet burden, number of tablets and the size of the tablets for patients. We also want to make sure that the program makes economic sense.”
> “We think those doses chosen in the SUNRISE program reflect both of those and I think give us a very nice potency range there.”

Source: [Viking Therapeutics third quarter 2026 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/714458-q3-2026/)

> “We would want to have no more than two tablets as the higher dose option. Lower doses would be one tablet. In the phase II trial, everybody took four tablets, and the feedback we received was that's just people weren't real satisfied with that.”

Source: [Viking Therapeutics first quarter 2026 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/555372-q1-2026/)

<a id="heading-3.1.4.6"></a>

### 3.1.4.6 Study Outcomes

<a id="heading-3.1.4.6.1"></a>

#### 3.1.4.6.1 Rationale for Using Percent Change in Body Weight as the Primary Endpoint

<a id="topic-3.1.4.6.1-1"></a>

##### Primary endpoint: percent change in body weight at week 68

> “Percent change in body weight for participants with type 2 diabetes mellitus receiving VK2735 orally once daily”
> “To demonstrate that VK2735 daily oral is superior to placebo for percent change in body weight from baseline to week 68”

Source: [ClinicalTrials.gov NCT07868939](https://clinicaltrials.gov/study/NCT07868939)

> “The primary endpoint of both trials is the percent change in body weight from baseline for participants receiving oral VK2735 as compared to placebo after 68 weeks of treatment.”

Source: [Viking Therapeutics SUNRISE initiation release (2026)](https://ir.vikingtherapeutics.com/2026-10-14-Viking-Therapeutics-Announces-Initiation-of-VK2735-Oral-Phase-3-Clinical-Program-in-Patients-with-Obesity)

<a id="topic-3.1.4.6.1-2"></a>

##### Secondary and exploratory endpoints

> “Secondary and exploratory endpoints will evaluate a range of additional safety and efficacy metrics, including the percentage of patients who achieve ≥ 5%, ≥ 10%, ≥ 15% or ≥ 20% body weight reduction from baseline.”

Source: [Viking Therapeutics SUNRISE initiation release (2026)](https://ir.vikingtherapeutics.com/2026-10-14-Viking-Therapeutics-Announces-Initiation-of-VK2735-Oral-Phase-3-Clinical-Program-in-Patients-with-Obesity)

> “Secondary endpoint: Percentage of patients with ≥5%, ≥10%, ≥15%, ≥20% weight loss”
> “Exploratory endpoints: Changes in function, metabolic health, mental health, productivity”

Source: [Viking Therapeutics corporate presentation (2026)](https://ir.vikingtherapeutics.com/download/Viking+Therapeutics+Corporate+Presentation+November+2026.pdf)

<a id="topic-3.1.4.6.1-3"></a>

##### FDA draft guidance: primary efficacy endpoint for weight-reduction drugs

> “The efficacy of a weight-reduction drug in adults should be assessed by analyses of mean”
> “percentage change from baseline body weight in the investigational drug group versus the”
> “In general, a drug is considered effective for weight reduction and maintenance in patients with”
> “obesity or overweight with comorbidities if, after 1 year of treatment at the maintenance dosage,”
> “the difference in mean percentage weight reduction between the investigational drug and control-”
> “treated groups is at least 5% and the difference is statistically significant.”

Source: [FDA weight reduction draft guidance (2025)](https://www.fda.gov/media/71252/download)

<a id="topic-3.1.4.6.1-4"></a>

##### FDA draft guidance: weight reduction indication spans at least one year

> “The weight reduction indication comprises the concepts of both initial weight loss and weight maintenance (i.e., prevention of weight regain) for a minimum of 1 year.”

Source: [FDA weight reduction draft guidance notice (2025)](https://www.govinfo.gov/content/pkg/FR-2025-01-08/html/2025-00237.htm)

<a id="heading-3.1.4.7"></a>

### 3.1.4.7 Statistical Analysis Description

<a id="heading-3.1.4.7.1"></a>

#### 3.1.4.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.4.7.1-1"></a>

##### Planned enrollment

> “SUNRISE-1 and SUNRISE-2 will each target enrollment of 560 adults.”

Source: [Viking Therapeutics SUNRISE initiation release (2026)](https://ir.vikingtherapeutics.com/2026-10-14-Viking-Therapeutics-Announces-Initiation-of-VK2735-Oral-Phase-3-Clinical-Program-in-Patients-with-Obesity)

> “560”

Source: [ClinicalTrials.gov NCT07868939](https://clinicaltrials.gov/study/NCT07868939)

<a id="topic-3.1.4.7.1-2"></a>

##### Basis for the reduced sample size: reuse of subcutaneous safety data

> “We're leveraging the subq human data, and that allows us to shrink the sizes of the studies from a total of about 5,600, 5,700 in the phase III subq down to 75% lower than that.”

Source: [Viking Therapeutics Morgan Stanley conference transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/744429-morgan-stanley-24th-annual-global-healthcare-conference/)

<a id="heading-3.1.4.7.2"></a>

#### 3.1.4.7.2 Description of Analysis Sets

<a id="topic-3.1.4.7.2-1"></a>

##### Superiority hypothesis for the primary endpoint

> “To demonstrate that VK2735 daily oral is superior to placebo for percent change in body weight from baseline to week 68”

Source: [ClinicalTrials.gov NCT07868939](https://clinicaltrials.gov/study/NCT07868939)

<a id="topic-3.1.4.7.2-2"></a>

##### Analysis populations

No evidence found.

<a id="heading-3.1.4.8"></a>

### 3.1.4.8 Results

<a id="heading-3.1.4.8.1"></a>

#### 3.1.4.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.4.8.2"></a>

#### 3.1.4.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.4.8.3"></a>

#### 3.1.4.8.3 Efficacy Results

No evidence found.

<a id="heading-3.1.4.8.4"></a>

#### 3.1.4.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.4.8.5"></a>

#### 3.1.4.8.5 Safety Results

No evidence found.

<a id="heading-3.1.4.9"></a>

### 3.1.4.9 Study Limitations

<a id="topic-3.1.4.9-1"></a>

#### Summary

SUNRISE-2 had reported no results as of November 2026, and every leaf on disposition, baseline characteristics, efficacy, quality of life, and safety is empty. The design is known only from the ClinicalTrials.gov record, company press releases, an investor presentation, and transcripts of investor calls; no protocol, statistical analysis plan, or peer-reviewed design paper is available.

The registry and the company documents differ on status, doses, and population. The company announced the program's initiation on October 14, 2026, and its later documents describe the trials as “Underway”, while the registry record still lists the study as “Not yet recruiting” with an estimated start in November 2026. The registry describes the three active arms only as dose levels 1 to 3; the doses of 27.5 mg, 35 mg, and 55 mg are stated in company releases. The company describes participants as “obese or overweight”, while the registry's inclusion criteria are a body mass index of 27 kg/m2 or more with type 2 diabetes and an HbA1c of 7% to 11%.

The registry record lists one primary outcome and no secondary outcomes, so the responder endpoints and the exploratory endpoints rest on company documents, and neither source names HbA1c as an outcome. Participants treated with GLP-1 receptor agonists, dual GLP-1/GIP receptor agonists, DPP-4 inhibitors, or amylin analogues are excluded, and the registry names diet, exercise, and oral glucose-lowering agents as permitted background therapy. The planned enrollment of 560 participants per trial is about 75% smaller than the subcutaneous phase 3 program, a reduction the company attributes to reusing safety data from the subcutaneous trials, which the FDA accepted while noting “risks going from phase II to phase III”. The company states that the doses were chosen in part to lower “the tablet burden” and for gross margin. The FDA's details from the end-of-phase 2 meeting are not public, and the company declined to describe them. Primary completion is estimated 3 months later than for SUNRISE-1 (October 2028 against July 2028).

Source: [ClinicalTrials.gov NCT07868939](https://clinicaltrials.gov/study/NCT07868939); [ClinicalTrials.gov NCT07868835](https://clinicaltrials.gov/study/NCT07868835); [Viking Therapeutics SUNRISE initiation release (2026)](https://ir.vikingtherapeutics.com/2026-10-14-Viking-Therapeutics-Announces-Initiation-of-VK2735-Oral-Phase-3-Clinical-Program-in-Patients-with-Obesity); [Viking Therapeutics third quarter 2026 results release (2026)](https://ir.vikingtherapeutics.com/2026-10-28-Viking-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update); [Viking Therapeutics corporate presentation (2026)](https://ir.vikingtherapeutics.com/download/Viking+Therapeutics+Corporate+Presentation+November+2026.pdf); [Viking Therapeutics third quarter 2026 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/714458-q3-2026/); [Viking Therapeutics fourth quarter 2025 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/401860-q4-2025/); [Viking Therapeutics Jefferies conference transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/678533-jefferies-global-healthcare-conference-2026/); [Viking Therapeutics Morgan Stanley conference transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/744429-morgan-stanley-24th-annual-global-healthcare-conference/)

## Related pages
- [VK2735: Chronic weight management](https://www.evicenter.com/drugs/vk2735--chronic-weight-management) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management.md)
- [VK2735 in Chronic weight management: Terms and abbreviations](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/terms-and-abbreviations.md)
- [VK2735: Chronic weight management](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/executive-summary) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/executive-summary.md)
- [VK2735 in Chronic weight management: Product information and disease description](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description.md)
- [VK2735 in Chronic weight management: Clinical evidence](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/clinical-evidence.md)
- [VK2735 in Chronic weight management: Economic information and modeling report](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/economics) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/economics.md)
- [VK2735 in Chronic weight management: References](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/references) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/references.md)
